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esponsibility of InstAbstract HCV genotypes have been documented in clinical practice. The aim of this study was
to determine the replication priority of different HCV genotypes in a Chinese HCV positive cohort.
Serum samples from 491 apparently healthy Chinese blood donors testing positive for HCV
antibodies and naive to antiviral drug therapy were tested. Genotyping analysis showed that
genotypes 1b and 2a were predominant and accounted for 77.6% of the HCV infections. Among the
genotype groups, individuals infected with genotype 2a had an HCV RNA viral load (108 copies/mL)
about 200-fold (lg, 2.3) greater than those infected with other genotypes (104–105 copies/mL) indicating a
replication priority of genotype 2a. However, there was no correlation between HCV genotype and
antibody response suggesting that the ampliﬁcation advantage of genotype 2a results from a favorable
interaction with the host cellular environment. In conclusion, HCV genotypes 1b and 2a are the
predominant genotypes in China and genotype 2a possesses a signiﬁcant replication priority compared1
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Table 1 Blood viral RNA load in
Genotype Group s
1a 33(13/2
1b 204(80/
2a 177(77/
2b 33(11/2
3a 13(3/10
3b 9(3/6)
6 12(2/10
Unidentiﬁed 10(5/5)
aNumber of subjects.
bStandard error.
c1b vs 2a, using unpaired Student's
Replication priority study of HCV genotypes in Chinese 267with the other genotypes. This suggests the existence of host cellular factors that may act as drug-targets
for entirely clearing HCV infection in the future.
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Hepatitis C virus (HCV) belongs to the family Flaviviridae and is a
single-stranded RNA virus with genetic variability. The genetic
diversity extends to seven major genotypes with 30–35% difference
at the nucleotide level1. In relation to the response to antiviral
therapy, HCV genotypes 2 and 3 show a greater therapeutic
response to interferon/ribavirin regimen than the other genotypes
especially in the initial stages of treatment2,3. Epidemiologically,
genotype 1 is the most widespread globally and is the most
prevalent of the seven; genotypes 2 and 3 are common in the
far East; genotype 4 has been documented in the Middle East
and North Africa, genotype 5a in South Africa and genotype 6 in
Southeast Asia4–6. HCV genotypes are also associated with
disease progression; for instance, Japan-speciﬁc HCV genotype 1b
(J subtype) shows a low pathogenicity7. To further understand
the biological signiﬁcance of HCV genotypes, we investigated the
prevalence, viral replication priority and characteristics of the
antibody response for each of the genotypes in blood samples from
an HCV positive Chinese cohort of blood donors not previously
treated with any antiviral agent. The results provide an opportunity
to examine the HCV replication capacity of the different genotypes
in an infection course free of drug intervention.2. Materials and methods
2.1. Serum samples
Serum samples from 491 seemingly healthy blood donors (297
male, 194 female; age range 18–60; average age 36.8) collected at
the Langfang Blood Center (about 200 miles South of Beijing,
China) were selected based on a positive test for HCV antibodies
and no history of antiviral drug therapy (i.e. this was the ﬁrst timeindividuals infected with differen
izea (female/male) HC
Me
0) 1.6
124) 6.1
100) 1.1
2) 2.9
) 1.6
1.7
) 4.3
3.3
t-test.HCV antibodies were detected). Of the 491 individuals, 166
showed an elevated liver transaminase indicating an abnormality
in their liver function. Blood was collected into EDTA tubes
followed by serum isolation by centrifugation at 1000 rpm for
10 min at room temperature. Serum samples were stored at
80 1C prior to testing. The study was approved by the Research
Committees of the Institute of Medicinal Biotechnology, Chinese
Academy of Medical Sciences, and the National Institutes for
Food and Drug Control.2.2. HCV testing
Serum HCV antibodies were detected using the Abbott HCV anti-
body detection kit (Axsym System HCV version 3.0). Quantitation
of HCV RNA was done using the Cobas HCV RNA kit (Roche,
New Jersey). HCV genotyping was carried out using a kit from
Ningbo Ruixin Biotech Inc. (Ningbo, China) and a Boao-5800
microarray reader (Beijing, China). To explore the antibody re-
sponse characteristics of each HCV genotype, the antibody reac-
tion to the HCV epitope antigens Core, NS3, NS4 and NS5 was
examined using an HCV antibody detection kit from Jin-Wei-Kai
Biotech Inc. (Beijing, China). All tests were performed in tri-
plicate according to the manufacturers' instructions. The antibody
response was taken as positive when the average S/C value 41.
The antibody positive rate to HCV epitopes of serum was cal-
culated as positive number detected/total number detected 100%.2.3. Statistical methods
Differences in mean viral load among study groups were tested
using the Student's t-test for equal or unequal variances depending
on a preliminary F test for homogeneity of variance.t HCV genotypes.
V RNA viral load (copy/mL) Pc
an SEb
3 104 3.67 103
7 105 3.70 105 0.006
2 108 4.89 107
1 104 1.15 103
7 104 6.66 103
8 104 3.67 103
1 105 3.64 103
1 105 5.03 104
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3.1. HCV prevalence
Of the 491 blood donors, infection with the different genotypes
was as follows: 1a 33 (6.7%); 1b 204 (41.5%); 2a 177 (36.0%); 2b
33 (6.7%); 3a 13 (2.6%); 3b 9 (1.8%); 6 12 (2.4%); and
unidentiﬁed 10 (2.0%). Thus the predominant HCV genotypes in
this Chinese cohort were 1b and 2a accounting for a total of 77.6%
of HCV infection. The results are consistent with previous
reports8,9.
3.2. HCV viral load
The viral load in serum samples was determined to investigate the
correlation between HCV genotype and viral replication. As
shown in Table 1, the highest viral load is seen in the genotype
2a group and is signiﬁcantly greater than in the 1b group
(Po0.01) by about 200-fold (lg, 2.3). The other genotypes had
an average viral load below that of genotype 1b.
These results suggest that, although HCV genotypes 1b and 2a
have almost identical infectivity in northern China, genotype 2a
appears to have a greater ability to proliferate in the natural course
of HCV infection. There could be at least two possible explana-
tions for this: ﬁrst, the antibody response could be different among
the genotypes; and second, the advanced proliferation capacity of
genotype 2a might result from a favorable interaction between 2a
and host cellular factors.
3.3. HCV speciﬁc antibodies
We then aimed to explain why genotype 2a ampliﬁes more than
the other genotypes. The analysis was focused on the antibody
response to the major HCV epitope antigens, Core, NS3, NS4 and
NS5 and to determine the proportion of individuals in each
genotype group who had positive antibody responses to each of
the HCV epitope antigens. As shown in Fig. 1, the antibody
positivity rates are 80%–97% for NS3, 84%–91% for Core, 10%–
51% for NS4 and 10%–48% for NS5. The overall ranking of
antibody positivity to the epitopes followed the order NS3 (95%)
4Core (89%)4NS4 (47%)4NS5 (36%) and appears to apply to
all genotypes. The results suggest that, among the HCV epitope
antibodies, those against NS3 and Core are the early biomarkers of
HCV infection. As individuals infected with different HCVFigure 1 Antibody response to HCV epitopes in different genotype
groups. The data show the antibody positivity rate to the four HCV
epitopes in each genotype group.genotypes exhibited a similar pattern of antibody response against
the four HCV epitopes, HCV genotypes did not appear to correlate
with the epitope-speciﬁc antibody responses. Thus, antibody
response in HCV infection does not account for the replication
priority of genotype 2a and suggests that intrinsic factors in
genotype 2a infection play an important role after HCV enters the
host cells.
3.4. HCV and liver damage
As hepatocyte apoptosis is involved in the pathogenesis of HCV
infection10,11, the high proliferation capacity of HCV genotype 2a
may cause a rapid progression of liver damage. Indeed, we found
that the GPT (glutamate-pyruvate transaminase) level in the group
infected with genotype 2a was higher than in the genotype 1b
group (Po0.001, 80716 vs 6778) indicating a faster progression
of liver damage during the early stages of infection. However, viral
load may not necessarily correlate with the blood level of liver
transaminase and, indeed, the difference in GPT values may not be
clinically signiﬁcant.4. Discussion
HCV is a positive single-stranded RNA virus belonging to the
Flaviviridae family and the causative agent for hepatitis C around
the world. Interferon in combination with ribavirin has become the
standard pharmacotherapy for chronic hepatitis C over the past few
decades12. However, three NS3-4A protease inhibitors (telaprevir,
boceprevir and simeprevir) and one NS5B RNA dependent RNA
polymerase (RdRp) inhibitor (sofosbuvir) have recently been
approved by the US FDA for anti-HCV treatment13,14 leading to
the expectation that an all-oral, interferon-free combination of
drugs will provide a cure for more than 90% of infections.
Nevertheless, these new drugs have yet to make a signiﬁcant
impact on the prevalence of HCV infection15 and it remains to be
seen how they will deal with resistant HCV.
In patients with HCV infection, HCV genotype 2a is sensitive
to standard-of-care treatment and sustained virological response
(SVR) is higher in those infected with genotype 2a than in those
infected with other genotypes2,16. The reason for this remains
unclear. There are some reports that Interleukin-28B, or other IFN-
stimulated genes (ISGs) may inﬂuence the SVR during treatment
with interferons or interferon plus ribavirin17,18 but this does not
explain why they are not so efﬁcient in treating those infected with
other genotypes. Interestingly, the recently approved RdRp inhi-
bitor sofosbuvir also showed higher response rates in those
infected with genotype 2 than in those infected with other
genotypes19 suggesting viral factors are not alone in inﬂuencing
therapeutic outcomes. Our results show that, although HCV
genotypes 1b and 2a have equal prevalence in northern China,
genotype 2a has a signiﬁcant replication advantage which may
partly explain its high sensitivity to combination therapy with
alpha-interferon plus ribavirin or sofosbuvir plus ribavirin. Con-
sidering the small group size for those infected with genotypes 3a,
3b and 6 in the present study, a well-designed investigation with
more subjects is needed to validate the results in these genotypes.
It is known that many factors can inﬂuence viral replication
including immunity, age, hepatocellular damage and whether the
infection is acute or chronic. The limited results presented here
indicate that HCV genotype 2a has replication priority over other
HCV genotypes during the natural course of HCV infection and
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environment is more supportive of genotype 2a than of genotype
1b or other HCV genotypes. In fact, in Huh-7 cell lines, the only
permissive cell lines for HCV infection20, genotype 2a did show a
proliferation rate higher than that of other HCV genotypes21,22 in
agreement with our observations. The suggestion of more rapidly
progressing liver damage in the genotype 2a group found here is
also consistent with its higher replication level although the
difference in GPT levels may not be clinically signiﬁcant.
In conclusion, HCV genotypes 1b and 2a are the predominant
HCV genotypes in our Chinese cohort of which genotype 2a has
the replication priority in the natural course of HCV infection. This
may result from a favorable interaction between genotype 2a and
host cellular factors which, in turn, accelerates the progress of liver
damage during the early stages of infection. These results may be
useful in the search for new host cellular factors as drug-targets for
entirely clearing HCV infection in the future.Acknowledgments
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